Epigenetic inactivation of the CHFR gene in cervical cancer contributes to sensitivity to taxanes

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 713-720

  Banno, Kouji ^a   Yanokura, Megumi ^a   Kawaguchi, Makiko ^a   Kuwabara, Yoshiko ^a   Akiyoshi, Jyunko ^a   Kobayashi, Yusuke ^a   Iwata, Takashi ^a   Hirasawa, Akira ^a   Fujii, Takuma ^a   Susumu, Nobuyuki ^a   Tsukazaki, Kastumi ^a   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cervical cancer; Chemosensitivity; CHFR; DNA hypermethyltion; Taxane

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; BRIDGED COMPOUND; CELL CYCLE PROTEIN; CHFR PROTEIN, HUMAN; DNA; SMALL INTERFERING RNA; TAXANE; TAXOID; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ARTICLE; CELL CULTURE; COLLOID CARCINOMA; DNA METHYLATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG TOLERANCE; FEMALE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX TUMOR;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZACITIDINE; BRIDGED COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE PROTEINS; DNA METHYLATION; DNA, NEOPLASM; DRUG TOLERANCE; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); RNA, SMALL INTERFERING; TAXOIDS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 35848946152     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.713     Document Type: Article

References (29)

1. Beral V, Hermon C, Muñoz N and Devesa SS: Cervical cancer. Cancer Surv 19-25: 265-285, 1994.
2. Parker SL, Tong T, Bolden S and Wingo PA: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
3. Scheffiner M, Werness BA, Huibregtse JM, Levine AJ and Howly PM: The E6 oncoprotein ebcode by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63: 1129-1135, 1990.
4. Dyson N, Howley PM, Münger K and Harlow E: The human papillomavirus 16 E7 oncoprotein is able to bund to the retinoblastoma gene product. Science 243: 934-937, 1989. (Pubitemid 19066153)
5. Nakashima R, Fujita M, Enomoto T, Haba T, Yoshino K, Wada H, Kurachi H, Sasaki M, Wakasa K, Inoue M, Buzard G and Murata Y: Alteration of p16and p15 gene in human uterine tumors. Br J Cancer 80: 458-467, 1999. (Pubitemid 29213201)
6. Yu MY, Tong JH, Chan PK, Lee TL, Chan MW, Chan AW, Lo KW and To KF: Hypermethylation of the tumor suppressor gene RASSF1A and frequent concomitant loss of heterozygosity at 3p21 in cervical cancers. Int J Cancer 105: 204-209, 2003.
7. Kuzmin I, Liu L, Dammann R, Geil L, Stanbridge EJ, Wilczynski SP, Lerman MI and Pfeifer GP: Inactivation of RAS assoiciation domain family 1A gene in cervical carcinomas and the role of human papillomavirus infection. Cancer Res 63: 1888-1893, 2003.
8. Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H and Imai K: Inactivation of the 4-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. Cancer Res 60: 4353-4357, 2000.
9. Satoh A, Toyota M, Itoh F, Sasaki Y, Suzuki H, Ogi K, Kikuchi T, Mita H, Yamashita T, Kojima T, Kusano M, Fujita M, Hosokawa M, Endo T, Tokino T and Imai K: Epigenetic inactivation of CHFR and sensitivity to microtubule inhibitors in gastric cancer. Cancer Res 63: 8606-8613, 2003. (Pubitemid 38064034)
10. Scolnick DM and Halazonetis TD: Chfr defines a mitotic stress checkpoint that delays entry into metaphase. Nature 406: 430-435, 2000.
11. Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai T and Tokino T: Epigenetic inactivation of CHFR in human tumors. Proc Natl Acad Sci USA 100: 7818-7823, 2003. (Pubitemid 36760053)
12. Yanokura M, Banno K, Kawaguchi M, Hirao N, Hirasawa A, Susumu N, Tsukazaki K and Aoki D: Relationship of abbarant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer. Oncol Rep 17: 41-48, 2007.
13. Susumu N, Aoki D, Noda T, Nagashima Y, Hirao T, Tamada Y, Banno K, Suzuki A, Suzuki N, Tsuda H, Inazawa J and Nozawa S: Diagnostic clinical application of two-color fluorescence in situ hybridization that detects chromosome 1 and 17 alterations to direct touch smear and liquid-based thinlayer cytologic preparations of endometrial cancers. Int J Gynecol Cancer 15: 70-80, 2005.
14. Kawaguchi M, Banno K, Susumu N, Yanokura M, Kuwabara Y, Hirao N, Tsukazaki K and Nozawa S: Successful analysis of anticancer drug sensitivity by CD-DST using pleural fluid and ascites from patients with advanced ovarian cancer: case reports. Anticancer Res 25: 3547-3551, 2005. (Pubitemid 41105239)
15. Tokunaga E, Oki E, Nishida K, Koga T, Yoshida R, Ikeda K, Kojima A, Egashira A, Morita N, Kakeji Y and Maehara Y: Aberrant hypermethylation of the promoter region of the CHFR gene is rare in primary breast cancer. Breast Cancer Res Treat 97: 199-203, 2006.
16. Corn PG, Summers MK, Fogt F, Virmani AK, Halazonetis TD and EL-Deiry WS: Frequent hypermethylation of the 5′ CpG island of the mitotic stress checkpoint gene Chfr in colorectal and non-small cell lung cancer. Carcinogenesis 24: 47-51, 2003.
17. Mizuno K, Osada H, Konishi H, Tatematsu Y, Yatabe Y, Mitsudomi T, Fujii Y and Takahashi T: Aberrant hypermethylation of the CHFR prophase checkpoint gene in human lung cancers. Oncogene 21: 2328-2333, 2002.
18. Sasieni P and Adams J: Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 357: 1490-1493, 2001. (Pubitemid 32488859)
19. Bray F, Carstensen B, Moller H, Zappa M, Zakelj MP, Lawrence G, Hakama M and Weidrepass E: Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 14: 2191-2199, 2005. (Pubitemid 41603267)
20. Wang SS, Sherman ME, Hildesheim A, Lacey JV and Devesa S: Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in United States for 1976-2000. Cancer 100: 1035-1044, 2004.
21. Berek JS, Hacker NF, Fu YS, Sokale JR, Leuchter RC and Lagasse LD: Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. Obstet Gynecol 65: 46-52, 1985.
22. Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R and Terakawa N: Prognosis and clinopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have radical hysterectomy. Eur J Surg Oncol 26: 464-467, 2000.
23. Bulk S, Visser O, Rozendaal L, Verheijen RH and Meijer CJ: Incidence and survival rate of women with cervical cancer in the Greater Amsterdam area. Br J Cancer 89: 834-839, 2003.
24. Yu X, Minter-Dykhouse K, Malureanu L, Zhao WM, Zang D, Merkle CJ, Ward JM, Saya H, Fang G, van Deursen J and Chen J: Chfr is required for tumor suppression and Aurora A regulation. Nat Genet 37: 401-406, 2005.
25. Hu W, Kavanagh JJ, Deaver M, Johnston DJ, Freedman RS, Verschraegen CF and Sen S: Frequent overexpression of STK15/Aurora-A/BTAK and chromosomal instability in tumorigenic cell cultures derived from human ovarian cancer. Oncol Res 15: 49-57, 2005.
26. Li JJ, Weroha SJ, Lingle WL, Papa D, Salisbury JL and Li SA : Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci USA 101: 18123-18128, 2004.
27. Fraizer GC, Diaz MF, Lee IL, Grossman HB and Sen S: Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 25: 1631-1639, 2004.
28. Thigpen JT, Blessing JA, Fowler WC Jr and Hatch K: Phase II trials of cisplatin and piperazinedione as single agent in the treatment of advanced or recuirrent non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Cancer Treat Rep 70: 1097-1100, 1986.
29. Curtin JP, Blessin JA, Webster KD, Rose PG, Mayer AR, Fowler WC Jr, Malfetano JH and Aivares RD: Paclitaxel, an active agent in non-squamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 17: 761-766, 1999.